Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial

Goudie, Andrew; Lipworth, Brian J.; Hopkinson, Pippa; Li, Wei; Struthers, Allan D.

doi:10.1016/s2213-2600(14)70013-x

Cited by 113 publications

(90 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Published experience with targeted PAH drug therapy is scarce, and so far there is no evidence from RCTs suggesting that PAH drugs result in improved symptoms or outcomes in patients with lung disease [411][412][413][414][415][416].…”

Section: Therapymentioning

confidence: 99%

See 1 more Smart Citation

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

et al. 2015

View full text Add to dashboard Cite

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

show abstract

Section: Therapymentioning

confidence: 99%

“…The use of drugs approved for PAH is not recommended in patients with PH due to lung diseases C III [411][412][413][414][415][416] CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; RHC: right heart catheterization. (Figure 4).…”

Section: Iiamentioning

confidence: 99%

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In contrast, PDE 5 inhibitors have been investigated in patients with COPD and (concomitant) pulmonary hypertension. Treating patients with COPD-associated pulmonary hypertension with sildenafil or tadalafil did not improve exercise capacity or quality of life [49,50].…”

Section: Phosphodiesterase 5 (Pde 5 )mentioning

confidence: 94%

Role of the nitric oxide–soluble guanylyl cyclase pathway in obstructive airway diseases

Dupont

Glynos²,

Bracke

et al. 2014

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

a b s t r a c tNitric oxide (NO) is a gaseotransmitter, which is involved in many signaling processes in health and disease. Three enzymes generate NO from L-arginine, with citrulline formed as a by-product: neuronal NO synthase (nNOS or NOS1), endothelial NOS (eNOS or NOS3) and inducible NOS (iNOS or NOS2). NO is a ligand of soluble guanylyl cyclase (sGC), an intracellular heterodimer enzyme that catalyzes the conversion of guanosine triphosphate (GTP) to cyclic GMP (cGMP). cGMP further activates protein kinase G that eventually reduces the smooth muscle tone in bronchi or vessels. Phosphodiesterase 5 (PDE 5 ) degrades cGMP to GMP. However, NO reacts with superoxide anion (O À 2 ), leading to formation of the proinflammatory molecule peroxynitrite.Under physiological conditions, NO plays a homeostatic bronchoprotective role in healthy subjects. In obstructive airway diseases, NO can be beneficial by its bronchodilating effect, but could also be detrimental by the formation of peroxynitrite. Since asthma and COPD are associated with increased levels of exhaled NO, chronic inflammation and increased airway smooth muscle tone, the NO/sGC/cGMP pathway could be involved in these highly prevalent obstructive airway diseases. Here we review the involvement of NO, NO synthases, guanylyl cyclases, cGMP and phophodiesterase-5 in asthma and COPD and potential therapeutic approaches to modulate this pathway.

show abstract

“…Liczba badań dotyczących stosowania famakoterapii swoistej dla PAH jest niewielka, a do tej pory nie ma dowodów pochodzących z RCT, które wskazywałyby, że leki stosowane w PAH poprawiają objawy lub rokowanie u pacjentów z chorobami płuc [411][412][413][414][415][416].…”

Section: Leczenieunclassified

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè¹,

Humbert²,

Vachiéry³

et al. 2015

Kardiol Pol

386

528

View full text Add to dashboard Cite

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial

Abstract: Chief Scientist Office for Scotland.

Cited by 113 publications

References 29 publications

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Role of the nitric oxide–soluble guanylyl cyclase pathway in obstructive airway diseases

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Contact Info

Product

Resources

About